Contact
Please use this form to send email to PR contact of this press release:
IcanoMAB GmbH Founded with Private Funding to Develop Precision Canonical Monoclonal Antibodies in Oncology, Immune-Modulation, Acute Inflammation and Most Urgently for Covid-19
TO: